The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Treatment combinations being explored with belantamab mafodotin in multiple myeloma
Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, highlights some treatment combinations being explored with belantamab mafodotin and clinical trials investigating these regimens, including DREAMM-6 (NCT03544281), DREAMM-14 (NCT05064358), and DREAMM-5 (NCT04126200). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research Funding: GSK, Amgen, Daiichi Sankyo, Cosette
Advisory board: BMS
Consultancy: Curio Science LLC, Intellisphere LLC
Membership on an entity’s Board of Directors or advisory committees: GSK
